Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers

Journal of Biomedical Science

Volumn 7, Issue 5, 2000, Pages 341-356

  Ling, Morris ^a   Kanayama, Masahide ^a   Roden, Richard ^a   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigens, tumor specific; Cervical cancer; Immunotherapy; T lymphocyte, cytotoxic; Tumor immunology; Vaccine

Indexed keywords

CANCER VACCINE; LIVE VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; KERATINOCYTE; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VACCINATION; VIRUS CAPSID; VIRUS PARTICLE; WART VIRUS;

ANIMALIA; HUMAN PAPILLOMAVIRUS; MIRIDAE;

EID: 0033824046     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/BF02255810     Document Type: Review

References (158)

1. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25;1997.
2. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 183:1287-1292;1996.
3. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72: 8220-8229;1998.
4. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed. Papillomavirus Rep 3:23-26;1992.
5. Benyacoub J, Hopkins S, Potts A, Kelly S, Kraehenbuhl JP, Curtiss R 3rd, De Grandi P, Nardelli-Hacfliger D. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infect Immun 67:3674-3679;1999.
6. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16:562-565;1998.
7. Bonnez W, Kashima HK, Leventhal B, Mounts P, Rose RC, Reichman RC, Shah KV. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 188:384-387;1992.
8. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347: 1523-1527;1996.
9. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14:1485-1494;1996.
10. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4:1069-1076;1997.
11. Brandsma JL. Animal models for HPV vaccine development. Papillomavirus Rep 5:105-111; 1994.
12. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:3959-3963; 1995.
13. Bubenik J, Simova J, Hajkova R, Sobota V, Jandlova T, Smahel M, Sobotkova E, Vonka V. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 14:593-597;1999.
14. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74:945-953;1993.
15. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-787;1997.
16. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10-16; 1997.
17. Chang EY, Chen C-H, Ji H, Wang T-L, Hung K, Lee BP, Huang AYC, Kurman RJ, Pardoll DM, Wu T-C. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 86: 725-730;2000.
18. Chen C-H, Suh KW, Ji H, Choti MA, Pardoll DM, Wu T-C. Antigen-specific immunotherapy for HPV-16 E7-expressing tumors grown in liver. J Hepatol (in press);2000.
19. Chen C-H, Wang T-L, Hung C-F, Pardoll DM, Wu T-C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 18:2015-2022;2000.
20. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM, Wu T-C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042;2000.
21. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 6:1972-1981;1999.
22. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5:231-252;1998.
23. Chen L, Ashc S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102;1992.
24. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224-231;1996.
25. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775-4787;1994.
26. Cheng WF, Hung CF, Slater LA, Yang YQ, Ling MF, Rodcn R, Wu TC. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of Sindbis virus self-replicating RNA vaccines against E7-expressing murine tumors, (manuscript in preparation);2000.
27. Cheng WF, Hung KF, Hsu KF, He L, Ling MF, Rice CM, Wu TC. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of antigen gene to an HSP70 gene, (manuscript in preparation);2000.
28. Cheng WF, Hung KF, Hsu KF, He L, Roden R, Wu TC. Enhancement of Semliki Forest virus self-replicating RNA vaccine potency by linkage of antigen gene to an HSP70 gene, (manuscript in preparation);2000.
29. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181: 572-579;1991.
30. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV, CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631;1997.
31. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128;1996.
32. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells cotransformed by HPV-16 plus EJ-ras. EMBO J 8:513-519;1989.
33. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91:765-775; 1997.
34. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 58:724-731;1998.
35. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564; 1989.
36. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 15:617-648;1997.
37. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 73:9063-9071;1999.
38. Edmonds C, Vousden KH. A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63:2650-2656;1989.
39. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte-epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249;1993.
40. Fernando GJ, Murray B. Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 115:397-403;1999.
41. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 13:1460-1467;1995.
42. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Stauss H. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 75:157-164; 1994.
43. Gonezol E, Berensci K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA. Preclinical evaluation of an ALVAC (canarypox) - Human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080-1085;1995.
44. Greenstone HL, Nieland JD, de Visser KE, Dc Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotcin in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805;1998.
45. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, Kenter MJ, Tulp A, Verwoerd D, Neefjes J. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci USA 96:10326-10331; 1999.
46. Hagensee ME, Carter JJ, Wipf GC, Galloway DA. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206: 174-182;1995.
47. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-322;1993.
48. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81:428-437;1999.
49. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 68:251-258;1986.
50. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 153:4925-4933;1994.
51. Hariharan K, Braslawsky G, Barnett RS, Berquist LG, Huynh T, Hanna N, Black A. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12:1229-1235; 1998.
52. Hart DN. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245-3287;1997.
53. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442-4446;1992.
54. Heufler C, Koch F, Schuler G. Granulocyte/ macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167: 700-705;1988.
55. Howley PM. Papillomavirinae: The viruses and their replication. Fields Virol 1:2045-2076;1996.
56. Hsu KF, Hung KF, Cheng WF, He L, Ling MF, Wu TC. Enhancement of suicidal DNA vaccine potency by linkage of antigen gene to an HSP70 gene. (manuscript in preparation); 2000.
57. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702; 1992.
58. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175:1157-1167; 1992.
59. Jarrett WF, Smith KT, O'Neil BW, Gaukroger JM, Chandrachud LM, Grindlay GJ, McGarvie GM, Campo MS. Studies on vaccination against papillomavimses: Prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184:33-42;1991.
60. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66:1329-1335;1992.
61. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78:41-45;1998.
62. 62 Ji H, Wang T-L, Chen C-H, Hung C-F, Pai S, Lin K-Y, Kurman RJ, Pardoll DM, Wu T-C. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 10:2727-2740;1999.
63. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14:115-120;1993.
64. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184;1992.
65. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37-44;1996.
66. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasiagrade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327: 1272-1278;1992.
67. Krul MR, Tijhaar EJ, Kleijne JA, Van Loon AM. Nievers MG, Schipper H, Geerse L, Van der Kolk M, Steerenberg PA, Mooi FR, Den Otter W: Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 43:44-48;1996.
68. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, Fallon RE, Roberts JS. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 179:612-618;1999.
69. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermund SH, Heyward WL, Nelson A, Reeves WC. Genital papillomavirus infection and cervical dysplasia - Opportunistic complications of HIV infection. Int J Cancer 50:45-48;1992.
70. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51-55;2000.
71. Li Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol 9:315-322;1997.
72. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August T, Pardoll DM, Wu T-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26;1996.
73. Lin YL, Borentein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187:612-619;1992.
74. Londono LP, Chatfield S, Tindle RW, Herd K, Gao XM, Frazer I, Dougan G. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 14:545-552;1996.
75. Lorinez AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 79:328-337;1992.
76. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR, Jansen KU. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176:1141-1145; 1997.
77. Lowy DR, Schiller JT. Papillomaviruses: Prophylactic vaccine prospects. Biochini Biophys Acta 1423:M1-8;1999.
78. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen DP, Strauss M, Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125:625-638;1994.
79. Lyman SD. Biology of flt 3 ligand and receptor. Int J Hematol 62:63-73;1995.
80. Lyman SD, Jacobsen SEW. c-kit ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101-1134;1998.
81. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1: 1297-1302;1995.
82. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 15:94-103;1997.
83. McMillan NA, Payne E, Frazer IH, Evander M. Expression of the alpha6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virology 261:271-279;1999.
84. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181: 62-69;1991.
85. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341-11348;1996.
86. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421; 1989.
87. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59:1184-1187; 1999.
88. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 65:3328-3336;1997.
89. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann NY Acad Sci 772:30-39;1995.
90. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte cpitopebased peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 18:86-94;1995.
91. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 55:4776-4779;1995.
92. Parr MB, Parr EL, Immunohistochemical localization of immunoglobulins A, G and M in the mouse female genital tract. J Reprod Fertil 74:361-370;1985.
93. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147-157;1998.
94. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-2427;1992.
95. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787-792;1997.
96. Plotkin SA, Cadoz M, Meignier B, Meric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, Gonczol E, Chappuis G. The safety and use of canarypox vectored vaccines. Dev Biol Stand 84:165-170;1995.
97. Price AA, Cumberbatch M, Kimber I, Ager A. Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J Exp Med 186:1725-1735;1997.
98. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154: 5934-5943;1995.
99. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 9:271-283;1997.
100. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70:3298-3301;1996.
101. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3: 849-854;1997.
102. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG, Inaba K, Steinman RM. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169:1169-1178:1989.
103. Rose RC, Lance C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 17:2129-2135;1999.
104. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spicss PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327;1998.
105. Rossi JL, Gissman L, Jansen K, Muller M. Assembly of infectious human papillomavirus type 16 virus-like particle in Saccharomyces cerevisiae. Hum Gene Ther 11:1165-1176;2000.
106. Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Muller M, Greenstone HL, Schiller JT, Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem 380:335-340; 1999.
107. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalck SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin b subunit. Infect Immun 64: 1272-1283;1996.
108. Sarkar AK, Tortolero-Luna G, Nehete PN, Arlinghaus RB, Mitchell MF, Sastry KJ. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol 8:165-174;1995.
109. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford E, Tommasino M. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126-135;1995.
110. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 164: 593-599;1991.
111. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81:881-888;1999.
112. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136;1990.
113. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 21: 2649-2654;1991.
114. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 5: 209-215;1999.
115. Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class 1-restricted epitope presentation. J Immunol 155:4676-4684; 1995.
116. Schmidt W, Buschle M, Zauner W, Kirlappos H. Mechtler K, Trska B, Birnstiel ML. Cellfree tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 94:3262-3267;1997.
117. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 60:602-605;1995.
118. Shah KV, Howley PM. Papillomaviruses. Fields Virol 1:2077-2109;1996.
119. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723-2730;1997.
120. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73:7877-7881;1999.
121. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 12:165-171;1997.
122. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296;1991.
123. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4:2103-2109;1998.
124. Stoler MH. Human papillomaviruses and cervical neoplasia: A model for carcinogenesis. Int J Gynecol Pathol 19:16-28;2000.
125. Stoler MH, Rhodes CR, Whitheck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23:117-128; 1992.
126. Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow LT. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 172:331-340;1989.
127. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92: 11553-11557;1995.
128. Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94:13146-13151; 1997.
129. Tagami H. Regression phenomenon of numerous flat wars - An experiment on the nature of tumor immunity in man. Int J Dermatol 22:570-571;1983.
130. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120;1997.
131. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758;1993.
132. Thapar MA, Parr EL, Parr MB. Secretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization. Immunology 70:121-125;1990.
133. Thompson HS, Davies ML, Holding FP, Fallon RE, Mann AE, O'Neill T, Roberts JS. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17:40-49; 1999.
134. Tighe H, Corr M, Roman M, Raz E, Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today 19:89-97;1998.
135. Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T, Fernando GJ. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1-and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol 101:265-271;1995.
136. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918;1996.
137. Toes RE, Hoeben RC, van der Voort EIH, Ressing ME, van der Eb AJ, Mclief CJM, Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruscs encoding multiple tumor-associated cytotoxic T lymphocyte cpitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 94:14660-14665;1997.
138. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860;1996.
139. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26:1317-1323;1998.
140. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-2707;1997.
141. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R. Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB. Vaccination with HPV 16 peptidcs of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur J Cancer 35: 946-952;1999.
142. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 113:393-399;1997.
143. Villanueva MS, Sijts AJ, Pamer EG. Listeriolysin is processed efficiently into an MHC class I-associated epitope in Listeria monocytogenes-infected cells. J Immunol 155:5227-5233;1995.
144. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19;1999.
145. Wang T-L, Ling L, Shih I-M, Pham T, Pai SI, Lu L, Kurman RJ, Pardoll DM, Wu T-C, Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther(in press);2000.
146. Wang TL, Slater LA, Hung CF, Yang YQ, Roden R, Wu TC. A LAMP-1 targeting strategy enhances the antitumor immunity of Scmliki Forest virus self-replicating RNA vaccines against E7-expressing murine tumors. (manuscript in preparation);2000.
147. Warnier G, Duffour MT, Uyttenhovc C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 67:303-310;1996.
148. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833-10837;1997.
149. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79;1990.
150. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484-1498;1987.
151. Wu TC. Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6:746-754;1994.
152. Wu TC, Guarnieri FG, Stavelcy OCKF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675; 1995.
153. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP. Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823-827; 1999.
154. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369-396;1996.
155. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833;1998.
156. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA. Antigen-specific tumor vaccines. Development and
157. Zhao KN, Sun XY, Frazer IH, Zhou J. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243: 482-491;1998.
158. Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 189: 592-599;1992.